Back

PCSK9 inhibitors: more volumes to come?

27 August 2017 (19:10 - 19:15)
Organised by:
Congress Presentation Part of: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in CVD prevention Endothelial function Open Access ESC Congress 2017

About the speaker

Photo
Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

2 More presentations in this session

Presentation thumbnail
PCSK9 inhibitors: the story continues.
Professor J. Chapman (Paris, FR)
Slides Video
Presentation thumbnail
Challenging the data.
Professor J. Chapman (Paris, FR) Professor P. Sever (London, GB)

Access the full session

Session thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in CVD prevention

The Event

Event poster

ESC Congress 2017

27 August 2017 19:10 CET
You may be interested in
thumbnail
Congress Presentation
Targeting the PCSK9 pathway: where do novel therapies fit in?
26 August 2022
thumbnail
Congress Presentation
PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study
18 April 2023
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on coronary plaque: a meta-analysis and trial sequential analysis
1 September 2025
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources